Liping Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liping Du has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Wenna Gao
Department of Ophthalmology Henan International Joint Research Laboratory for Ocular Immunology and Retinal Injury Repair, Henan Province Eye Hospital, The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China
2 shared publicationsBo Jin
Department of Ophthalmology Henan International Joint Research Laboratory for Ocular Immunology and Retinal Injury Repair, Henan Province Eye Hospital, The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China
1 shared publication- Bo Lei
Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China
1 shared publication Chao Chen
Department of Critical Care Medicine Henan Provincial People's Hospital, Zhengzhou University People's Hospital Zhengzhou Henan China
1 shared publicationFan Yang
Department of Ophthalmology, The 988th Hospital of People's Liberation Army Joint Logistic Force, Zhengzhou, Henan, PR China
1 shared publication- Fuzhen Li
Department of Ophthalmology Henan International Joint Research Laboratory for Ocular Immunology and Retinal Injury Repair, Henan Province Eye Hospital, The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China
1 shared publication
Latest Publications
Ifi27l2a Facilitates the Recruitment of Pathogenic T Cells by Retinal Microglia in the Initiation Phase of Experimental Autoimmune Uveoretinitis
The mechanisms by which pathogenic T cells enter the immune‐privileged retina at the onset of uveitis remain unclear. To identify regulatory targets that promote retinal inflammation, we established an experimental autoimmune uveoretinitis (EAU) model by immunizing C57BL/6J mice with IRBP 651–670 and dynamically evaluated retinal inflammation after induction; fundus lesions were prominent, with the first 14 days representing the initiation phase, Days 14–28 the amplification phase, Days 28–35 the peak phase, and Days 35–42 the regression phase. We characterized retinal cellular alterations from the pre‐inflammatory stage to the peak stage using single‐cell transcriptomic analysis, and found that retinal immune cells changed in parallel with EAU severity, while immune‐cell interactions were strongest on Day 14, especially between microglia and T cells through multiple chemokine‐related pathways. We then identified key cell populations and candidate targets through integrated analyses and functional validation, and Ifi27l2a emerged as a core gene associated with inflammatory and immune responses in retinal microglia on Day 14. In vitro knockdown of Ifi27l2a in LPS‐activated BV‐2 cells reduced inflammatory mediator production and abolished Th1/Th17 induction. In vivo targeting of Ifi27l2a attenuated EAU severity and restored the balance of T‐cell subsets. These findings indicate that microglia are highly activated before retinal inflammation becomes prominent and that Ifi27l2a regulates this early pathogenic process.
Ifi27l2a Facilitates the Recruitment of Pathogenic T Cells by Retinal Microglia in the Initiation Phase of Experimental Autoimmune Uveoretinitis
The mechanisms by which pathogenic T cells enter the immune‐privileged retina at the onset of uveitis remain unclear. To identify regulatory targets that promote retinal inflammation, we established an experimental autoimmune uveoretinitis (EAU) model by immunizing C57BL/6J mice with IRBP 651–670 and dynamically evaluated retinal inflammation after induction; fundus lesions were prominent, with the first 14 days representing the initiation phase, Days 14–28 the amplification phase, Days 28–35 the peak phase, and Days 35–42 the regression phase. We characterized retinal cellular alterations from the pre‐inflammatory stage to the peak stage using single‐cell transcriptomic analysis, and found that retinal immune cells changed in parallel with EAU severity, while immune‐cell interactions were strongest on Day 14, especially between microglia and T cells through multiple chemokine‐related pathways. We then identified key cell populations and candidate targets through integrated analyses and functional validation, and Ifi27l2a emerged as a core gene associated with inflammatory and immune responses in retinal microglia on Day 14. In vitro knockdown of Ifi27l2a in LPS‐activated BV‐2 cells reduced inflammatory mediator production and abolished Th1/Th17 induction. In vivo targeting of Ifi27l2a attenuated EAU severity and restored the balance of T‐cell subsets. These findings indicate that microglia are highly activated before retinal inflammation becomes prominent and that Ifi27l2a regulates this early pathogenic process.
- Open Access
- 6 September 2026
- Published by Wiley in Aging Cell
- Vol. 25 (9) , e70694
Twisting the End Game: How Telomere Chromatin Modifications Shape Telomere Maintenance
Cell division inevitably shortens telomeric DNA owing to the end‐replication problem. Eukaryotic chromosomes possess specialized telomere structures to maintain genomic stability. In most proliferative cells, telomerase adds telomeric repeats during S‐phase. In differentiated cells where telomerase is silenced, telomeres shorten progressively, thereby compromising genomic integrity. Consequently, cancer cells universally activate alternative telomere maintenance mechanisms during malignant transformation: ~80% reactivate telomerase, while a portion of the rest rely on BIR (break‐induced replication)–mediated homologous recombination‐based ALT (alternative lengthening of telomeres). Although these mechanisms are stable once established, the initial determinants influencing a cancer cell's choice remain poorly understood. This review discusses recent molecular insights into how telomeric chromatin properties profoundly impact this choice. After briefly introducing telomere chromatin characteristics and key players in its maintenance and dynamics, we discuss the mechanisms by which cancer cells acquire distinct telomere replication capabilities. In particular, we present an in‐depth analysis linking telomere heterochromatin status to ALT. Furthermore, based on recent advances, we propose a coupled feedforward loop model explaining how the ALT state becomes “locked in” once initiated. Finally, we offer novel perspectives on rational, telomere‐centric therapeutic interventions for ALT‐positive cancers, focusing on strategies designed to disrupt such feedforward loops by manipulating telomeric chromatin structure.
- 6 September 2026
- Published by Wiley in Aging Cell
- Vol. 25 (9) , e70694
Open AccessTwisting the End Game: How Telomere Chromatin Modifications Shape Telomere Maintenance
Cell division inevitably shortens telomeric DNA owing to the end‐replication problem. Eukaryotic chromosomes possess specialized telomere structures to maintain genomic stability. In most proliferative cells, telomerase adds telomeric repeats during S‐phase. In differentiated cells where telomerase is silenced, telomeres shorten progressively, thereby compromising genomic integrity. Consequently, cancer cells universally activate alternative telomere maintenance mechanisms during malignant transformation: ~80% reactivate telomerase, while a portion of the rest rely on BIR (break‐induced replication)–mediated homologous recombination‐based ALT (alternative lengthening of telomeres). Although these mechanisms are stable once established, the initial determinants influencing a cancer cell's choice remain poorly understood. This review discusses recent molecular insights into how telomeric chromatin properties profoundly impact this choice. After briefly introducing telomere chromatin characteristics and key players in its maintenance and dynamics, we discuss the mechanisms by which cancer cells acquire distinct telomere replication capabilities. In particular, we present an in‐depth analysis linking telomere heterochromatin status to ALT. Furthermore, based on recent advances, we propose a coupled feedforward loop model explaining how the ALT state becomes “locked in” once initiated. Finally, we offer novel perspectives on rational, telomere‐centric therapeutic interventions for ALT‐positive cancers, focusing on strategies designed to disrupt such feedforward loops by manipulating telomeric chromatin structure.
- 9 October 2025
- Published by Elsevier in Experimental Eye Research
- Vol. 261, 110691
The association of ARR3 genetic polymorphisms with pathologic myopia in Northern Chinese population
- 9 October 2025
- Published by Elsevier in Experimental Eye Research
- Vol. 261, 110691
The association of ARR3 genetic polymorphisms with pathologic myopia in Northern Chinese population